Vertex Pharmaceuticals Inc / Ma (VRTX): Joshua S Boger , director of Vertex Pharmaceuticals Inc / Ma sold 6,500 shares on Sep 21, 2016. The Insider selling transaction was reported by the company on Sep 23, 2016 to the Securities and Exchange Commission. The shares were sold at $91.16 per share for a total value of $590,332.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 16, 2016, Joshua S Boger (director) sold 6,500 shares at $92.44 per share price.On May 18, 2016, Amit Sachdev (EVP, Policy, Access & Value) sold 117 shares at $81.67 per share price.Also, On May 18, 2016, Paul M Silva (SVP & Corp Controller) sold 202 shares at $82.06 per share price.On May 18, 2016, Ian F Smith (EVP & CFO) sold 202 shares at $82.06 per share price.
Vertex Pharmaceuticals Incorporated: On Thursday, Sep 22, 2016 heightened volatility was witnessed in Vertex Pharmaceuticals Incorporated which led to swings in the share price. The shares opened for trading at $92.83 and hit $93.35 on the upside , eventually ending the session at $92.12, with a gain of 0.33% or 0.3 points. The heightened volatility saw the trading volume jump to 11,91,840 shares. The 52-week high of the share price is $134.71 and the company has a market cap of $22,825 M . The 52-week low of the share price is at $75.9.
Company has been under the radar of several Street Analysts.Vertex Pharmaceuticals Incorporated is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 109 from a previous price target of $105 .The Rating was issued on Sep 15, 2016.Vertex Pharmaceuticals Incorporated is Initiated by Raymond James to Mkt Perform. The Rating was issued on Sep 13, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 105 from a previous price target of $108 . The Rating was issued on Aug 16, 2016.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.